Common Contracts
2 similar Product Development Agreement contracts by King Pharmaceuticals Inc
ContractProduct Development Agreement • May 5th, 2020 • New York
THIS PRODUCT DEVELOPMENT AGREEMENT (“Agreement”) is made on June 18, 2008 (the “Effective Date”) by and between COREPHARMA LLC, a limited liability company, incorporated under the laws of New Jersey (“Core”), and KING PHARMACEUTICALS, INC., a corporation incorporated under the laws of Tennessee (“KPI”), and KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC., a Delaware corporation and wholly owned subsidiary of KPI (“King R&D”, and together with KPI, “King”). RECITALS: WHEREAS, King and Core are in the business of researching, developing, formulating and manufacturing pharmaceutical products; and WHEREAS, Core has certain expertise in formulating, manufacturing, and developing new formulations of metaxalone that present bioavailability profile that is higher than the Reference Product (as defined herein); WHEREAS, King possesses rights in certain intellectual property pertaining to product formulations of the active pharmaceutical ingredient metaxalone; WHEREAS, King desires to resear
PRODUCT DEVELOPMENT AGREEMENT BETWEEN COREPHARMA LLC AND KING PHARMACEUTICALS, INC. and KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. Note: Certain material has been redacted from this document and filed separately with the SEC pursuant to a...Product Development Agreement • August 7th, 2008 • King Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS PRODUCT DEVELOPMENT AGREEMENT (“Agreement”) is made on June 18, 2008 (the “Effective Date”) by and between COREPHARMA LLC, a limited liability company, incorporated under the laws of New Jersey (“Core”), and KING PHARMACEUTICALS, INC., a corporation incorporated under the laws of Tennessee (“KPI”), and KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC., a Delaware corporation and wholly owned subsidiary of KPI (“King R&D”, and together with KPI, “King”).
